Model of digital transformation of the organization of production for enterprises in the pharmaceutical industry

The article discusses the concept of digital transformation of pharmaceutical industries, which is based on a generalization of existing theoretical models of digital transformation, such as the Digital Maturity Assured Framework (DMF), as well as the Model of structuring elements of digital business transformation by George Westerman, Didier Bonnet and Andrew McAfee. Digital transformation is currently a necessary condition for the development of production systems and increasing the competitiveness of products. Global competition and the influence of external economic factors lead to a transition from mass production to flexible production systems operating on the basis of the concept of personalized medicine, only Industry 4.0 digital technologies capable of supporting the production of a drug at all stages of the life cycle can be the answer to this challenge. Based on the theoretical analysis, a three-phase model of digital transformation was formed, which was further substantiated by practical analytical data from pharmaceutical enterprises in the Russian Federation. This model includes three phases: engineering design (Phase I), associated with the development and implementation of engineering projects, technical and technological transformation (phase II), which involves the accumulation of technological potential through investment in intellectual production factors, after which the final stage begins digital transformation (phase III), associated with the active development of digital tools and the increasing role of information technology in production.